Tamar Hamosh Taddei MD
Assistant Professor of Medicine (Digestive Diseases)
Clinical, translational, and outcome research on hepatocellular carcinoma
Dr. Taddei is building clinical programs at Yale and the VA with a focus on multidisciplinary, integrated care of the patient with hepatocellular carcinoma. The goals of these programs are to contribute to scientific advances in treatment, improve healthcare delivery, decrease the time from diagnosis to treatment, and improve survival in patients with hepatocellular carcinoma. In collaboration with colleagues across a spectrum of disciplines, she will develop and implement clinical trials, translational projects, and outcome studies at Yale and the VA.
- Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis. 2011;15(2):423-41.
- Fox RK, Taddei T, Rose MG. Managing hepatocellular carcinoma through multidisciplinary care. Federal Practitioner 2010; 27 (suppl 10):1-6.
- Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, Cohen DE, Pastores G, Mistry PK. High incidence of cholesterol gallstone disease in Type 1 Gaucher Disease: characterizing the biliary phenotype of type 1 Gaucher Disease. Journal of Inherited Metabolic Diseases. 2010; 33(3):291-300. Epub 2010 Mar 31.
- Monto A, Kohlwes J, Raval GR, Mehta P, El-Serag HB, Taddei T. Managing advanced hepatocellular carcinoma. Multidisciplinary perspectives on management: a roundtable discussion. Federal Practitioner 2009; 26 (suppl 1):20-24.
- Taddei T. Managing advanced hepatocellular carcinoma: treating unresectable disease. Federal Practitioner 2009; 26 (suppl 1):15-19.
- Taddei TH, Kacena KA, Yang M, Yang M, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores G, and Mistry PK. The under-recognized progressive nature of N370S Gaucher Disease and high risk of cancer in 403 patients. American Journal of Hematology. 2009; 84:208-14.